C Sixty

C Sixty is an early stage, highly innovative and focused nanotechnology company pioneering the development of new drugs based on the unique chemistry of water-soluble fullerenes, a recently discovered class of highly structured, small molecules. Since our organization in 1999,we have secured and developed a strong intellectual property position covering the strategic biomedical uses of fullerenes.  Beginning in 2003, our company has focused its drug discovery efforts on the unprecedented antioxidant activity of fullerenes.

We believe that drugs based on fullerene antioxidant molecules may have significant impact on several unsolved diseases, including: Parkinson’s Disease, Alzheimer’s, Stroke, Atherosclerosis, complications from Diabetes, and protection of bone marrow cells from cancer chemotherapy and radiotherapy, each of which represent billion dollar annual market opportunities. We secured partnerships with at least two multinational life science partners (Merck and Unilever).  These partnerships currently involve evaluation of C Sixty’s drug candidates for specific target applications.

We are a wholly owned subsidiary of Carbon Nanotechnologies Inc, the leading producer and innovator in the area of single-walled carbon nanotubes, and is managed as an independent operating company.

Russ Lebovitz, MD, PhD

Visit C Sixty